Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

al compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; plans and timing for commercialization of Qutenza; and development activities for NGX-1998 and other product candidates, including regulatory submissions and any outcomes of such submissions. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: positive results in clinical trials may not be sufficient to obtain FDA approval; the FDA may request additional clinical trials or other information prior to granting approval for Qutenza; any regulatory approvals which are received may be limited to certain indications; inability or delay in establishing sales infrastructure to support potential commercialization; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy or tolerability; physician or patient reluctance to use Qutenza or NGX-1998, if approved; other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates; and our ability to raise additional capital as needed. For further information regarding these and other risks r
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... memory device for computing may have just taken an ... New York led by chemist Stephen O,Brien have discovered ... properties. , Combining both properties is very exciting scientifically ... for the devices that might ultimately be designed, in ... a single material, however, has proved difficult until now. ...
(Date:9/18/2014)... 18, 2014 September 24 marks ASEA's ... ASEA is the manufacturer of the world's first and ... product, RENU28. , The Mexico City event features ... Botero, and ASEA Field Leader Shawn Catmull from Draper, ... in Atomic/Medical Physics from the University of Utah and ...
(Date:9/17/2014)... , Sept. 17, 2014 A ... accelerated partial breast irradiation (APBI) via interstitial brachytherapy ... with positive lymph nodes could be suitable to ... Oncology (ASTRO) guidelines place these patients in the ... at the 2014 ASTRO meeting, Beaumont Health System,s ...
(Date:9/17/2014)... N.C. , Sept. 17, 2014  The In ... topics that will be featured at the conference, which ... Center on December 3 and 4, 2014. Researchers, students, ... invited to hear the following: KEYNOTE ... San Diego Skaggs School of Pharmacy ...
Breaking Biology Technology:Oxides discovered by CCNY team could advance memory devices 2Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4In Silico Drug Discovery Conference Announces Speakers and Topics 2In Silico Drug Discovery Conference Announces Speakers and Topics 3In Silico Drug Discovery Conference Announces Speakers and Topics 4In Silico Drug Discovery Conference Announces Speakers and Topics 5In Silico Drug Discovery Conference Announces Speakers and Topics 6In Silico Drug Discovery Conference Announces Speakers and Topics 7
... are used in a wide variety of applications ... and aerospace applications. Thermal analysis is routinely used ... growing trend to use nanostructured materials has made ... an atomic force microscope-based technique called nanoscale thermal ...
... laboratory has found a way to turn common carbon ... with properties expected to prove useful in electronic, optical ... scientist Pulickel Ajayan, in collaboration with colleagues in China, ... one-step chemical process that is markedly simpler than established ...
... cell therapy manufacturing division, Progenitor Cell Therapy ("PCT"), ... NBS ) ("NeoStem" or the "Company"), announced today ... and regulatory services related to the development of ... injectable suspension of microencapsulated insulin-producing, pancreatic islet cells ...
Cached Biology Technology:Magnetic actuation enables nanoscale thermal analysis 2Graphene quantum dots: The next big small thing 2Graphene quantum dots: The next big small thing 3Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing 2Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing 3Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing 4
(Date:9/18/2014)... 18, 2014 Elsevier, a world-leading provider of ... and the Australasian Research Management Society (ARMS), recognized ... at the 5th Scopus Young Researcher of the ... today at the National Convention Centre and in ... attended by guests representing Australia,s and New Zealand,s ...
(Date:9/18/2014)... of camouflage: you don,t just blend in, the background ... uncommon as you might think. Kathryn Feller, from the ... larval life stages of many marine species are transparent. ... most creatures cannot make transparent. Feller explains that the ... eye unit with an opaque pigment to prevent light ...
(Date:9/17/2014)... affordable health care to reproductive technologies, the justice ... ability of people to identify key issues, articulate ... and find the most defensible ways forward. But ... these societal conversations?, The Hastings Center and the ... have teamed up to publish a series of ...
Breaking Biology News(10 mins):Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Transparent larvae hide opaque eyes behind reflections 2Why bioethics literacy matters 2Why bioethics literacy matters 3
... Jizhou Song, a professor in the University of Miami ... Rogers, at the University of Illinois and Professor Yonggang ... for stretchable electronics that can be wrapped around complex ... The new mechanical design strategy is based on semiconductor ...
... Researchers from Joslin Diabetes Center, Boston, and ActiveSite ... have demonstrated that a specific inhibitor of the ... may provide a new therapeutic approach for treatment ... of diabetes. The study, which was partly funded ...
... that human male fertility is impacted by long-term exposure ... in the male reproductive tract, further suggesting a functional ... test to clarify mechanisms. Now, in a paper on ... the phenotype of mice genetically lacking FAAH, fatty acid ...
Cached Biology News:University of Miami engineer designs stretchable electronics with a twist 2Researchers describe protease inhibitor that may aid in diabetic retinopathy treatment 2Researchers describe protease inhibitor that may aid in diabetic retinopathy treatment 3February 2009 highlights from Biology of Reproduction 2
Smac/DIABLO (mouse) (CT) rabbit polyclonal antibody...
... to ADAMTS16 ( Abpromise for ... Antigen: Synthetic peptide based on ... Note: the amino acid sequence is ... 170690 SWISS ...
... Immunogen: KLH-conjugated, synthetic ... in which [ Ac K] corresponds to ... Accession Number: NM_003493 ... ~17kDa Quality Assurance: ...
synaptotagmin XIV-like [Source:RefSeq_peptide;Acc:NP_114120] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: